Revenue and profit forecasts fail to justify the hype baked into Moderna’s share price, according to Citi’s analysts.
Citi tells investors it’s time to sell Moderna after 600%-plus stock gains
Revenue and profit forecasts fail to justify the hype baked into Moderna’s share price, according to Citi’s analysts.
Sign in to your account